Data from AstraZeneca PLC and Oxford University’s non-US Phase III trials of their COVID-19 vaccine candidate will not be good enough to support an emergency use authorization by the US Food and Drug Administration, Operation Warp Speed’s Moncef Slaoui predicts.
Slaoui is chief scientific advisor to OWS, and while he does not represent the FDA his view is likely to...





